EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury

Changhua Ji, Steven Kumpf, Jessie Qian, Joel D Federspiel, Mark Sheehan, Darien Capunitan, Edmond Atallah, Stuart Astbury, Seda Arat, Elias Oziolor, Mireia Fernandez Ocana, Shashi K Ramaiah und 3 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04033-z ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Changhua Ji und 14 weiteren Autor:innen. Beteiligte Einrichtung: Drug Safety R&D, Pfizer Inc, 10777 Science Center Dr., La Jolla, CA, 92121, USA. jichanghua5@gmail.com. Hauptthemen laut MEDLINE: Biomarkers, Chemical and Drug Induced Liver Injury, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and PD-1 have shown remarkable antitumor efficacy, but can also cause immune-related adverse events, including checkpoint inhibitor-induced liver injury (ChILI). This multi-omic study aimed to investigate changes in blood samples from treated cancer patients who developed ChILI. PBMCs were sequenced for by transcriptomic and T cell receptor repertoire (bulk and single-cell immune profiling), and extracellular vesicle (EV) enrichment from plasma was analyzed by mass spectroscopy proteomics. Data were analyzed by comparing the ChILI patient group to the control group who did not develop ChILI and by comparing the onset of ChILI to pre-ICI treatment baseline. We identified significant changes in T cell clonality, gene expression, and proteins in peripheral blood mononuclear cells (PBMCs) and plasma in response to liver injury. Onset of ChILI was accompanied by an increase in T cell clonality. Pathway analysis highlighted the involvement of innate and cellular immune responses, mitosis, pyroptosis, and oxidative stress. Single-cell RNA sequencing revealed that these changes were primarily found in select T cell subtypes (including CD8 + effector memory cells), while CD16 + monocytes exhibited enrichment in metabolic pathways. Proteomic analysis of plasma extracellular vesicles showed enrichment in liver-associated proteins among differentially expressed proteins. Interestingly, an increase in PBMC PD-L1 gene expression and plasma PD-L1 protein was also found to be associated with ChILI onset. These findings provide valuable insights into the immune and molecular mechanisms underlying ChILI as well as potential biomarkers of ChILI.Trial registration number NCT04476563.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersChemical and Drug Induced Liver InjuryImmune Checkpoint InhibitorsNeoplasmsProteomicsTranscriptomeAgedFemaleHumansMaleMiddle AgedLeukocytes, Mononuclear

Stichwörter der Autor:innen

BiomarkerChILICheckpoint inhibitorLiver injuryPD-L1

Substanzen

BiomarkersImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Drug Safety R&D, Pfizer Inc, 10777 Science Center Dr., La Jolla, CA, 92121, USA. jichanghua5@gmail.com.
  • Drug Safety R&D, Pfizer Inc, Eastern Point Rd, 274-3715A, Groton, CT, 06340, USA.
  • Drug Safety R&D, Pfizer, Andover, MA, USA.
  • Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
  • NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
  • Drug Safety R&D, Pfizer, Cambridge, MA, USA.

Förderung

  • Pfizer

Zitieren

APA

Ji, C., Kumpf, S., Qian, J., Federspiel, J. D., Sheehan, M., Capunitan, D., Atallah, E., Astbury, S., Arat, S., Oziolor, E., Ocana, M. F., Ramaiah, S. K., Grove, J., Aithal, G. P., & Lanz, T. A. (2025). Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04033-z

Vancouver

Ji C, Kumpf S, Qian J, Federspiel JD, Sheehan M, Capunitan D, et al. Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04033-z

BibTeX
@article{Ji2025,
  author = {Ji, Changhua and Kumpf, Steven and Qian, Jessie and Federspiel, Joel D and Sheehan, Mark and Capunitan, Darien and Atallah, Edmond and Astbury, Stuart and Arat, Seda and Oziolor, Elias and Ocana, Mireia Fernandez and Ramaiah, Shashi K and Grove, Jane and Aithal, Guruprasad P and Lanz, Thomas A},
  title = {Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04033-z}
}
Kostenlos starten →